News >

Expert Provides Guidelines for Diagnosis and Management of TA-TMA

Virginia Powers, PhD
Published: Wednesday, Apr 03, 2019

Sonata Jodele, MD

Sonata Jodele, MD

While complex, criteria for diagnosing transplant-associated thrombotic microangiopathy (TA-TMA) following hematopoietic stem cell transplantation (HSCT) should be closely followed and should begin with screening, according to a presentation during the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.

These criteria changed somewhat until the current guidelines were accepted, which comprise:
  1. LDH above normal for age,
  2. Schistocytes on peripheral blood smear,
  3. De novo thrombocytopenia/required platelet transfusions,
  4.  De novo anemia or required red blood cell transfusions
  5. Hypertension >99% for age, 140/90, or antihypertensive therapy
  6. Proteinuria ≥30 mg/dL (2 measurements) or urine protein creatinine ratio ≥2 mg/mg,
  7. Terminal complement activation elevated above normal (≥244 ng/mL).
Jodele proposed that diagnosis be based upon presence of 4 of the above 7 laboratory and clinical markers and noted that proteinuria and complement activation are high-risk markers for TMA. She commented that ADAMTS13 activity may be reduced in TMA but remains >10%, elevated haptoglobin is a poor prognostic marker, and serum creatinine is a late occurring marker that is only useful if elevated, especially in children.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication